28.06.2018 • NewsElaine BurridgeOxea

Oxea Hikes German NPG Capacity

Oxea Hikes German NPG Capacity (c) Oxea
Oxea Hikes German NPG Capacity (c) Oxea

German oxo-chemicals company Oxea has announced plans to increase capacity for neopentyl glycol (NPG) at its site in Oberhausen. Basic engineering on the debottlenecking project has started and the additional output is expected to be available by early 2020. Capacity figures were not disclosed.

“We are convinced that the NPG market is growing.  But while capacities for NPG are being added in Asia, European capacities are not expanding in line with demand growth,” said Matthias Freitag, Oxea’s global commercial business director polyols and plasticizers. He added that based on customer requirements, Oxea will produce NPG molten, 90% slurry and flakes, for small to large industrial customers. NPG is used in the synthesis of polyesters, coatings, lubricants and plasticizers.

Separately, the Monheim-based group confirmed that its new propanol production plant at Bay City, Texas, USA, is now mechanically complete. The 100,000 t/y Propanol 2 facility is scheduled to produce commercial volumes in the third quarter.

Naoko Roth, Oxea’s marketing director US oxo intermediates, said that with the additional capacity, Oxea can expand further into existing and future growth markets.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.